A quarter of a million children die of tuberculosis (TB) each year worldwide. Early diagnosis would help save lives.
The potential for Actiphage to be used as a mainstream diagnostic for human tuberculosis (TB) has been investigated in a study across the University Hospitals of Leicester (Leicester’s Hospitals) with promising results.
Traditional tests rely on sputum to detect the infection but almost half of all people with pulmonary TB are unable to produce sputum, particularly in early disease.
It also difficult to culture the mycobacteria for plate detection.
Actiphage provides a novel approach: it is able to detect the presence of live mycobacteria in a sample of blood.
It uses a bacteriophage – a virus specific to the mycobacteria that causes TB. The bacteriophage is able to penetrate the tough membrane of the bacteria and release DNA from live cells, which can then be identified.
The results from initial trials are very promising.
Results from a further study were presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (2022) more information and link to the abstract.
A total of 1.5 million people died from TB in 2020 (WHO data). Worldwide, TB is second only to COVID-19 as the most fatal infectious disease.
Children are often overlooked by health providers as the disease is particularly difficult to detect using current diagnostics.
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom